ReviewWorld journal of urology2012
Androgen receptor co-activators in the regulation of cellular events in prostate cancer.
Review in World journal of urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive review.Frontiers in pharmacology · 2024Review
- Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation-Drug leads for metastatic castration resistant prostate cancer.SLAS discovery : advancing life sciences R & D · 2023Article
- AR activates YAP/TAZ differentially in prostate cancer.Life science alliance · 2023Article
- Review
- The Hippo pathway: an emerging role in urologic cancers.American journal of clinical and experimental urology · 2021Review
- The BET-inhibitor PFI-1 diminishes AR/AR-V7 signaling in prostate cancer cells.World journal of urology · 2019Article
- High Content Positional Biosensor Assay to Screen for Compounds that Prevent or Disrupt Androgen Receptor and Transcription Intermediary Factor 2 Protein-Protein Interactions.Methods in molecular biology (Clifton, N.J.) · 2018Article
- Expression and clinical significance of androgen receptor in bladder cancer: A meta-analysis.Molecular and clinical oncology · 2017Article
- Reconfiguring the AR-TIF2 Protein-Protein Interaction HCS Assay in Prostate Cancer Cells and Characterizing the Hits from a LOPAC Screen.Assay and drug development technologies · 2016Article
- Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer.Oncotarget · 2015Review
- FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.Oncotarget · 2015Article
- YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer.Nature communications · 2015Article
- High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions.Assay and drug development technologies · 2014Article
- The link between androgen receptor splice variants and castration-resistant prostate cancer.Hormones & cancer · 2014Review
- Coactivator MYST1 regulates nuclear factor-κB and androgen receptor functions during proliferation of prostate cancer cells.Molecular endocrinology (Baltimore, Md.) · 2014Article
- Nrf1 and Nrf2 transcription factors regulate androgen receptor transactivation in prostate cancer cells.PloS one · 2014Article
- Article
- Unveiling the association of STAT3 and HO-1 in prostate cancer: role beyond heme degradation.Neoplasia (New York, N.Y.) · 2012Article
- Molecular aspects of prostate cancer.World journal of urology · 2012Article
- Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor.Assay and drug development technologiesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAndrogen receptor (AR) action in benign and malignant tissue is potentiated by a number of co-regulatory proteins that may interact with one or more receptor domains. With improvement of research methodologies, it became possible to detect a number of co-activators whose expression is increased in prostate cancer tissue.
methodsManuscripts describing prostate cancer-relevant regulation of cellular events by co-activators are selected and summarized.
resultsAR co-activators may regulate histone modification, proteasomal degradation, chaperones, sumoylation, chromatin remodeling, and cytoskeleton. Some of them (TIF-2) are up-regulated by androgens, whereas the expression of others increases during androgen ablation (p300, CBP, and Tip60). Most co-factors are important for the stimulation of cellular proliferation, although in some cases (ART-27), they act as tumor suppressors and are deleted in prostate cancer tissue. In addition to stimulating AR, some co-activators suppress apoptosis in prostate cancer cells that do not express the AR (p300 and SRC-3). It was recently shown that the inhibition of p300 slows down proliferation, stimulates apoptosis, and inhibits migration and invasion.
conclusionsCo-factors whose down-regulation results in the alterations of multiple cellular functions may be valid targets for novel therapies in advanced prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.